From January 2016 to December 2020， 165 patients with a median age of 52 years were enrolled. According to the simple random method， 55 cases in group A， with 11 males and 44 females， were treated with ZOL at the end of treatment， and 110 cases in group B， with 34 males and 76 females， were treated without ZOL at the end of the same period and followed up regularly. The changes of alkaline phosphatase， serum calcium， serum phosphorus and renal function in the two groups were compared and evaluated （before the first medication and after the last follow-up in group A， and after the first follow-up and the last follow-up in group B）. SPSS 19.0 software was used for statistical analysis. After descriptive analysis was used to test the normal distribution and homogeneity of variance， the mean value was compared with independent samplet-test； Paired samplet-test was used for comparison between groups.

The follow-up rate of 165 cases was 99.39%， and the median follow-up time was 37 months. There was no difference in the enrollment and disease characteristics between the two groups （P> 0.05）. There was no significant difference between the two groups （P> 0.05）. Analysis between groups： before and after treatment， serum calcium in group a decreased （t= 3.757，P< 0.001）， the difference was statistically significant， and there was no difference in the changes of residual alkaline phosphatase， serum phosphorus and renal function.

The serum calcium level of patients with solid tumor without bone metastasis decreases after early intervention with ZOL. Early intervention of solid tumor SREs by ZOL has a certain effect on calcium metabolism.